Grant Directory

Verified government funding opportunities

Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional

Open

National Institutes of Health

Deadline: federal

Updated: Oct 30, 2025

Summary

The grant aims to fund research for the discovery and development of non-addictive analgesic therapeutics to address the opioid crisis, specifically targeting early optimization and Phase I development activities. Eligible applicants include government entities, educational institutions, for-profit and small businesses, and nonprofit organizations with 501(c)(3) status. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborations and projects in anticipation of the upcoming funding opportunity.

Full Description

Description

Twelve NIH Institutes, including NINDS, NEI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDCR, NIDDK, NIDA, NCCIH and NCI intend to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research focused on the discovery and development of small molecule and biologic non-addictive analgesic therapeutics to treat pain. This study is part of the NIH Helping to End Addiction Long -term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The goal of the program is to accelerate the optimization and development of promising early therapeutic molecules and to facilitate readiness for Phase II clinical studies. Through this NOFO, the NIH offers researchers funding for drug discovery and development activities that can be conducted in their own laboratories. Researchers also have the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in critical areas associated with therapeutics development. The scope of this program spans early optimization through Phase I development activities. It is expected that all projects will be entering first in human studies at the end of the grant period either through NIH contracts or funds requested in the grant application. This is a milestone-driven, phased, cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress. The scope of this program excludes basic research, therapeutic device development and clinical studies beyond Phase I studies. Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will use the UG3/UH3 activity code. Investigators with expertise and insights into pain therapeutics development are encouraged to consider applying for this revised NOFO. In addition, applications from collaborating investigators combining expertise in pain biology, drug development, clinical testing and statistical design will be encouraged to consider applying for this funding opportunity.

Eligibility

Eligible applicants

Government

  • Public and Indian housing authorities
  • State governments
  • Federally recognized Native American tribal governments
  • County governments

Education

  • Private institutions of higher education
  • Public and state institutions of higher education
  • Independent school districts

Business

  • For-profit organizations other than small businesses
  • Small businesses

Nonprofit

  • Nonprofits non-higher education with 501(c)(3)
  • Other Native American tribal organizations

Additional information

Grantor contact information

Description

--

Email

mohamed.hachicha@nih.gov

mohamed.hachicha@nih.gov

Apply on official siteUpdated Oct 30, 2025

Recommended Resource

Grant Writing Services on Fiverr

Top Pick

Struggling with grant applications? Get expert help from professional freelance writers on Fiverr — from research and proposal drafts to compliance review and submission. Secure funding faster with proven talent.